NCT04956289 - Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

June 20, 2023

Study Completion Date

July 13, 2023

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG

Viltolarsen

Received during weekly intravenous infusions

Trial Locations (8)

Children's Hospital of Richmond at VCU, Richmond

Yeditepe University Kosuyolu Hospital, Istanbul

Russian National Research Medical University, Moscow

Saint Petersburg State Paediatric Medical University, Saint Petersburg

Hunan Children's Hospital, Changsha

The Third Medical Center of PLA General Hospital, Beijing

Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Roma

Hospital Sant Joan de Deu, Barcelona